Pharma & Biotech - Page 16

Launched earlier this year, TrumpRx is a White House initiative designed to give patients access to drugs priced in line with what other developed nations pay. The administration has branded this approach

ITM Isotope Technologies Munich SE has received a Complete Response Letter from the U.S. Food and Drug Administration, blocking approval of its cancer drug ITM-11. The FDA issued the CRL on August

Abbott Laboratories (ABT) has signed telenovela star Gabriela Spanic to front a Spanish-language campaign promoting colorectal cancer screening among Hispanic adults in the United States. Spanic rose to international fame through the

President Donald Trump signed an executive order on August 10, 2026, titled “Delivering Gold Standard Childhood Vaccine Recommendations for Americans,” narrowing the recommended childhood vaccine list. The order reduces the number of

The prolonged Strait of Hormuz standoff is deepening concerns across pharmaceutical supply chains, with no resolution appearing imminent from either side. President Trump has signalled the US is prepared to let economic

Tenax Therapeutics (Nasdaq: TENX) has announced that its Phase 3 LEVEL clinical trial evaluating TNX-103, an oral form of levosimendan, failed to meet its primary endpoint. The trial, which enrolled 241 patients

Bristol Myers Squibb (NYSE: BMY) has selected Houston, Texas, as the location for a new multi-modal manufacturing campus representing approximately $2.3 billion in investment. The facility will be built at Generation Park

Bristol Myers Squibb (NYSE: BMY) has announced plans to build a major new manufacturing campus in Houston, Texas, representing a $2.3 billion investment in domestic production capacity. The facility will be located

Health insurers and pharmacy benefit managers are growing increasingly cautious about how the TrumpRx drug pricing programme could reshape the prescription medication landscape for patients. The initiative introduces federal pricing benchmarks that

AstraZeneca and Bristol Myers Squibb have no ongoing discussions about a potential merger, according to a senior source close to the matter cited by Reuters. “There is no deal between AstraZeneca and